ニュース

Seeking Alpha

Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline

The company expects to complete recruitment for the Phase III LUCIDITY trial of Avexitide by the end of 2025, with top line data anticipated in the first half of 2026. Top line data from the Phase IIb ...